The role of targeted therapies in HER2+ and HR+ breast cancer

Early Breast Cancer HR+ HER2- New Study ResultsПодробнее

Why Comprehensive Genomic Profiling (CGP) is Important in HR+/HER2- Advanced Breast CancerПодробнее

Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast CancerПодробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 InhibitionПодробнее

The Role of Biomarkers in Breast Cancer TestingПодробнее

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast CancerПодробнее

Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast CancerПодробнее

Foundation Frontiers: Advanced Breast Cancer - Updates to HR+/HER2- Treatment LandscapeПодробнее

Navigating the Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast CancerПодробнее

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Ca...Подробнее

HERA: the role of ovarian suppression in HR-positive HER2+ breast cancerПодробнее

Samarth Life | Current Treatment Options in HR+ve & HER2-ve Metastatic Breast CancerПодробнее

Hormone Receptor Status in Breast Cancer (ER, PR or HER2 status) | Dr Vivek Belathur | PrecisionПодробнее

How Nurses Maximize the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast CancerПодробнее

New Targeted Therapy Options for ER Positive, HER2 Negative, Advanced Breast CancerПодробнее

Current and future HER2+, HR- metastatic breast cancer treatment approachesПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Addressing Current Questions and Controversies in the Management of Metastatic Breast CancerПодробнее